Biogen Inc

Biogen Inc. discovers develops manufactures and delivers therapies for treating neurological and neurodegenerative diseases in the United States Europe Germany Asia and internationally. The company offers TECFIDERA VUMERITY AVONEX PLEGRIDY TYSABRI and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI an etanercept biosimilar referencing ENBREL; IMRALDI an adalimumab biosimilar referencing HUMIRA; FLIXABI an infliximab biosimilar referencing REMICADE; and BYOOVIZ a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma chronic lymphocytic leukemia (CLL) rheumatoid arthritis two forms of ANCA-associated vasculitis and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition the company is developing various products for the treatment of MS Alzheimer's disease and dementia neuromuscular disorders Parkinson's disease and movement disorders neuropsychiatry immunology related diseases neurovascular disorders genetic neurodevelopmental disorders and biosimilars which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co. Ltd.; Genentech Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals Inc.; Samsung Bioepis Co. Ltd.; Sangamo Therapeutics Inc.; and Sage Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge Massachusetts.